Atomo Diagnostics Ltd已向澳大利亚证券交易所提交交易暂停申请，旨在就美国食品药品监督管理局针对其Febridx产品CLIA豁免申请的最新回应进行信息披露。本次交易暂停将延续至公司正式发布相关公告或2024年7月3日开盘前。
作为全球领先的快速诊断解决方案提供商，Atomo Diagnostics专注于开发创新型指尖血自测设备。Febridx系列产品是其核心研发项目，此次CLIA豁免申请若获通过，将显著拓展该产品在美国零售市场的应用场景。
公司表示将尽快通过澳交所公告平台披露FDA回应的具体内容。交易暂停期间，投资者可通过公司官网及澳交所指定渠道获取最新进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.